Phytocannabinoids:Origins and Biosynthesis by Gülck, Thies & Møller, Birger Lindberg
u n i ve r s i t y  o f  co pe n h ag e n  
Phytocannabinoids
Origins and Biosynthesis
Gülck, Thies; Møller, Birger Lindberg
Published in:
Trends in Plant Science
DOI:
10.1016/j.tplants.2020.05.005
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Gülck, T., & Møller, B. L. (2020). Phytocannabinoids: Origins and Biosynthesis. Trends in Plant Science, 25(10),
985-1004. https://doi.org/10.1016/j.tplants.2020.05.005
Download date: 03. Dec. 2020
Trends in Plant ScienceFeature ReviewPhytocannabinoids: Origins and BiosynthesisThies Gülck1,2,3,* and Birger Lindberg Møller1,2,3,*Highlights
Phytocannabinoids are bioactive terpe-
noids that were thought to be exclusive
to Cannabis sativa, but have now also
been discovered in Rhododendron spe-
cies, some legumes, the liverwort genus
Radula, and some fungi.
Many cannabinoids display promising
non-hallucinogenic bioactivities that are
determined by the variable nature of the
side chain and prenyl group defined by
the enzymes involved in their synthesis.
The biosynthesis of cannabinoids inPhytocannabinoids are bioactive natural products found in some flowering
plants, liverworts, and fungi that can be beneficial for the treatment of human
ailments such as pain, anxiety, and cachexia. Targeted biosynthesis of cannabi-
noids with desirable properties requires identification of the underlying genes
and their expression in a suitable heterologous host. We provide an overview
of the structural classification of phytocannabinoids based on their decorated
resorcinol core and the bioactivities of naturally occurring cannabinoids, and
we review current knowledge of phytocannabinoid biosynthesis in Cannabis,
Rhododendron, and Radula species. We also highlight the potential in planta
roles of phytocannabinoids and the opportunity for synthetic biology approaches
based on combinatorial biochemistry and protein engineering to produce canna-
binoid derivatives with improved properties.C. sativa is fully elucidated, whereas the
pathways in Rhododendron and Radula
have only recently gained research
attention.
Cannabinoid biosynthesis is highly
modular, enabling use of the modules
identified in synthetic biology-based
combinatorial approaches, as demon-
strated by the generation of new-to-
nature cannabinoids in Saccharomyces
cerevisiae.
The ecological functions of cannabinoids
include protection against UV light and
desiccation, as well as in plant defense.
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The term phytocannabinoid (see Glossary, also cannabinoid) defines meroterpenoids with a
resorcinyl core typically decorated with a para-positioned isoprenyl, alkyl, or aralkyl side chain [1].
The alkyl side chain typically contains an odd number of carbon atoms, where orcinoids contain
one carbon, varinoids three, and olivetoids five. Cannabinoids with an even number of carbon
atoms in the side chain are known but rare. The term cannabinoid generally refers to molecules
with a characteristic chemical structure; however, the term may also refer to pharmacological
ligands of human endocannabinoid receptors [2]. In this review we use the chemical definition
of cannabinoids.
Phytocannabinoids occur in flowering plants, liverworts, and fungi (Figure 1, Key Figure). They
were first isolated from Cannabis sativa L. (Cannabaceae), a plant with a long and controversial
history of use and abuse [3]. The mammalian brain has receptors that respond to compounds
found in C. sativa. Accordingly, these receptors were named cannabinoid receptors (CBx) and
are the basis of the endocannabinoid system. Studies in human and animals demonstrated
that the endocannabinoid system regulates a broad range of biological functions, including mem-
ory, mood, brain reward systems, and drug addiction, as well as metabolic processes such as
lipolysis, glucose metabolism, and energy balance [2]. More than 113 different cannabinoids
have been isolated from C. sativa and these are classified into distinct types: cannabigerols
(CBGs), cannabichromenes (CBCs), cannabidiols (CBDs), (−)-Δ9-trans-tetrahydrocannabinols
(Δ9-THCs), (−)-Δ8-trans-tetrahydrocannabinols (Δ8-THCs), cannabicyclols (CBLs), cannabielsoins
(CBEs), cannabinols (CBNs), cannabinodiols (CBNDs), cannabitriols (CBTs), and the miscella-
neous cannabinoids (Figure 2) [4]. C. sativa predominantly produces alkyl type cannabinoids that
carry a monoterpene isoprenyl moiety (C10) and a pentyl side chain (C5) [1]. The most abundant
constituents are trans-Δ9-THC, CBD, CBC, and CBG, together with their respective acid forms
(Δ9-THCA, CBDA, CBCA, and CBGA) [5]. Cannabinoid biosynthetic pathways typically generate
acidic cannabinoids (C22, 'pre-cannabinoids') as the final products [6]. Further modified cannabi-
noids are spontaneous breakdown or conversion products resulting from, for example, oxidation,
decarboxylation and cyclization, or are formed during isolation [7]. These conversions take place
because of the poor oxidative stability of alkylic cannabinoids, in particular Δ9-THC [1]. C. sativaTrends in Plant Science, October 2020, Vol. 25, No. 10 https://doi.org/10.1016/j.tplants.2020.05.005 985
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Glossary
Behavioral tetrad: the four distinct
behavioral changes that are associated
with the consumption of Δ9-
tetrahydrocannabinol (Δ9-THC):
hypothermia, catalepsy,
hypolocomotion, and analgesia.
Cytochrome P450 (CYP) enzymes: a
superfamily of heme-containing
enzymes that typically function as
monooxygenases.
Elepidotes: Rhododendron species
that lack glandular scales.
Endocannabinoid system: a
biological system in mammals based on
endocannabinoids that modulate
vegetative functions including pain,
sleep, mood, and appetite.
Gland cells: highly specialized cells for
the efficient and safe production and
storage of plant defense compounds
such as cannabinoids and terpenoids.
Based on their morphology, gland cells
are classified as glandular trichomes or
glandular scales.
Half-maximal effective
concentration (EC50): the
concentration of a compound that is
necessary to obtain its half-maximal
effect.
Lepidotes: Rhododendron species
possessing glandular scales.
Liverworts: a division of land plants
that are closely related to mosses.
Meroterpenoids: terpenoids whose
chemical structure also contains a
phenolic moiety derived from
phenylpropanoid metabolism.
Methylerythritol 4-phosphate (MEP)
pathway: this pathway is located in
plastids and generates the linear C5,
C10, C20, and C40 isoprenoid
precursors from which terpenoids are
formed.
Natural deep eutectic solvents
(NADES): these are composed of
specific molar ratios of polar and ionic
small molecules that via aqueous–
aqueous phase partitioning may
constitute a new phase in biological
systems. NADES are excellent solvents
for natural products and some enzymes.
Phytocannabinoids: a group of
specialized metabolites that were first
identified in Cannabis sativa. Extracts of
C. sativa contain the psychoactive Δ9-
THC as well as cannabidiol (CBD) that
offer beneficial health effects in humans.
Polyketide synthase (PKS): an
enzyme that catalyzes the synthesis of
polyketides by sequential elongation of
different types of starter molecules with
Key Figure
Illustration of the Structural Characteristics of Cannabinoids Found in
Different Plant Species
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Figure 1. Abbreviations: CBC, cannabichromene; CBCA, cannabichromenic acid; CBCV, cannabichromevarine; CBCVA,
cannabichromevarinic acid; CBD, cannabidiol; CBDA, cannabidiolic acid; CBDV, cannabidivarine; CBE, cannabielsoin;
CBG, cannabigerol; CBGA, cannabigerolic acid; CBL, cannabicyclol; Δ9-THC, Δ9-tetrahydrocannabinol; Δ9-THCA,
Δ9-tetrahydrocannabinolic acid; Δ9-THCAV, Δ9-tetrahydrocannabivarinic acid; Δ9-THCV, Δ9-tetrahydrocannabivarine.
Trends in Plant Scienceis the best-studied and most common and productive source of phytocannabinoids, but is not the
only organism capable of synthesizing this group of bioactive natural products.
Several Rhododendron species (Ericaceae) produce bioactive meroterpenoids with a cannabi-
noid backbone [8]. Rhododendron cannabinoids typically belong to the CBC type decorated986 Trends in Plant Science, October 2020, Vol. 25, No. 10
C2 carbon units derived from malonyl-
CoA.
Terpenoids: the largest group of
bioactive natural products of plants;
terpenoids are produced from
isoprenoid precursors of different chain
lengths.
Therapeutic index (TI): a quantitative
measurement of the relative safety of a
drug.
Trends in Plant Sciencewith an orcinol side chain (i.e., a methyl group).Rhododendron dauricum L. is native to Northeast-
ern Asia and produces grifolic acid (GFA), daurichromenic acid (DCA), and confluentin
(decarboxylated DCA), as well as rhododaurichromenic acids A and B. All these cannabinoids
carry a sesquiterpene moiety [9]. Rhododendron adamsii Rehder grows in the expanses of
Eastern Siberia and Mongolia and is used in folk medicine for preparing a stimulating tonic
and as an adaptogenic remedy [10]. It produces cannabigerorcynic acid, cannabigerorcynic
acid methylester, DCA, and chromane/chromene meroterpenoids [10]. Rhododendron
anthopogonoides Maxim. grows in Southern China and is used as expectorant and for the
treatment of chronic bronchitis [11,12]. Phytochemical studies revealed that it contains the
cannabinoid-like chromane and chromene derivatives anthopogocyclolic acid, anthopogochromenic
acid, cannabiorcichromenic acid, and cannabiorcicyclolic acid [11,12]. Lastly, Rhododendron
rubiginosum Franch. var. rubiginosum, a shrub endemic to Southwest China, was found to contain
anthopogochromenes A and B, as well as rubiginosins A–G [8].
The flowering plant Helichrysum umbraculigerum Less. (Asteraceae) from South Africa, the edible
roots of Glycyrrhiza foetida Desf. (licorice; Fabaceae), and Amorpha fruticosa L. (bastard indigo;
Fabaceae) contain so-called amorfrutins, bioactive compounds with a cannabinoid backbone
[13,14]. These cannabinoids carry an aralkyl side chain and are thus characterized as prenylated
bibenzyls [1,14].
Liverworts (Marchantiophyta; also called 'hepatics') are prolific producers of compounds with a
bibenzyl backbone, such as lunularic acid and vittatin [15]. Cannabinoids with a bibenzyl structure
have been isolated from Radula perrottetii Gottsche ex Steph., R. marginata Taylor ex Gottsche,
and R. laxiramea Steph. (Radulaceae), liverworts that are native to the northern island of
New Zealand. These bibenzyl analogs of Δ9-THC, (−)-cis-perrottetinene, and (−)-cis-
perrottetinenic acid are noteworthy for their inverted stereoconfiguration compared to non-
bryophyte cannabinoids [16–19].
Beyond plants, cannabinoids are present in a few fungal organisms. Mycorrhizal fungi of
the genus Albatrellus (Albatrellaceae) produce GFA and the derivatives grifolin, neogrifolin,
and confluentin [20,21]. Furthermore, Cylindrocarpon olidum (Nectriaceae) produces
cannabiorcichromenic acid and the halogenated cannabinoid 8-chlorocannabiorcichromenic
acid [22].
Sites of Phytocannabinoid Biosynthesis and Their Possible Functional Roles
C. sativa accumulates phytocannabinoids and terpenes in glandular trichomes located all over
the aerial parts of the plant and in highest density on the female flowers [7,23]. No glandular
trichomes are found on the root surfaces, and the root tissue therefore does not accumulate
phytocannabinoids [24]. Glandular trichomes may be classified as sessile trichomes or stalked
trichomes. Stalked glandular trichomes were recently shown to develop from sessile trichomes
[25]. Glandular trichomes accumulate cannabinoids in a balloon-shaped cavity that is filled by
secretory vesicles [25–28]. When a trichome ruptures, for example during high ambient temper-
atures or as a result of herbivory, its contents form a sticky coating on the plant surface that is
orchestrated by the viscous, non-crystallizing properties of cannabinoids [29]. The noxious
substance glues themandibles and legs of potential herbivores and prevents desiccation, resem-
bling the waxy glaze of cacti and other succulents from dry environments [30]. The amount of
cannabinoids formed correlates positively with increased temperatures and imposed heat stress,
as well as with low soil moisture and poor mineral nutrient content [31,32]. The latter was indi-
cated by a negative correlation between mineral supply and cannabinoid production [33,34].
Cannabinoid production may also provide an evolutionary advantage by functioning as sun-Trends in Plant Science, October 2020, Vol. 25, No. 10 987
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Figure 2. Overview of Cannabinoids Derived from an Orcinoid, Varinoid, Olivetoid, or Bibenzyl/Aralkyl Backbone. Black structures have been isolated from natural
sources [1]. Blue structures have not yet been found in planta. Abbreviations: CBC, cannabichromene; CBD, cannabidiol; CBE, cannabielsoin; CBG, cannabigerol; CBL,
cannabicyclol; CBN, cannabinol; CBND, cannabinodiol; CBT, cannabitriol; Pr, prenyl; SC, side chain; Δ8-THC, Δ8-tetrahydrocannabinol; Δ9-THC, Δ9-tetrahydrocannabinol.
Trends in Plant Sciencescreens that absorb biologically destructive UV-B radiation (280–315 nm) [35]. Significantly in-
creased cannabinoid production was measured in Cannabis flowers after UV-B-induced stress
[35]. Thus phytocannabinoids convey various biologically beneficial properties.988 Trends in Plant Science, October 2020, Vol. 25, No. 10
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cannabinoids in Rhododendron species. Rhododendrons are separated into two major groups,
elepidotes and lepidotes. Elepidotes are large-leaved rhododendrons that are devoid of scales
on their leaves. Lepidote rhododendrons have small leaves covered by glandular scales [36]. The
scales are located predominantly on the abaxial leaf surface, but are also present on the adaxial
side (ratio ca 20:1) [36]. These multicellular morphological features of epidermal origin consist of a
stalk and a circular expanded cap [36]. The leaf scales contain lipophilic globules that contain
specialized metabolites such as terpenes, and function in insect deterrence [37]. R. dauricum
produces DCA that accumulates in the apoplast of the glandular scales, presumably serving as
a chemical defense barrier based on its antimicrobial activities, together with its precursor grifolic
acid (GA) and the reaction side-product H2O2 [38].
Liverworts (Marchantiophyta) possess oil bodies – membrane-bound cell organelles containing
suspensions of terpenoids and aromatic oils in a carbohydrate- or protein-enriched matrix
[39]. The morphology of the oil bodies is used to distinguish the different Marchantiophyta spe-
cies, and oil bodies have been proposed to serve several ecological functions [40]. Liverworts
are in general not damaged by fungi and bacteria, insect larvae and adults, or slugs, snails, and
small mammals [39]. The compounds found in oil bodies bring forth characteristic pungent, odif-
erous, and/or bitter-tasting compounds that display a wide range of bioactivities [39]. It is note-
worthy that most sesqui- and di-terpenoids produced by liverworts show cis configuration, in
contrast to those found in most higher plants, which have trans configuration [41], although
sesqui- and di-terpenoids in the Eremophila genus and Solanum spp. are exceptions [42–45].
In addition, the proposed ecological functions of oil bodies include resilience to cold tempera-
tures, excessive light, UV radiation, and desiccation [40,46]. Liverworts are unable to
biosynthesize abscisic acid. Instead, they produce the bibenzylic dihydrostilbenoid lunularic
acid that has plant hormone activity [47]. The ecological function of perrottetinenic acid and
perrottetinene is unclear, but might resemble those of cannabinoids in C. sativa. An extensive
review on liverworts with a focus on Radula marginata taxonomy, genetics, cannabinoid
phytochemistry, and pharmacology was recently published by Hussain et al. [19]. Mosses
(Bryophyta) and hornworts (Anthocerotophyta) do not possess oil bodies [40,48].
Phytocannabinoids and Human Health
Cannabis preparations have been used as medicines since ancient times [3,49]. They have
been investigated for their antimicrobial activity against bacteria and fungi, and were found to
be effective against a range of infectious diseases in humans and to represent potent antibiotics.
Many fungi can metabolize cannabinoids [50], and this may reflect why cannabinoids seem to be
effective only against a few fungal pathogens such as Phomopsis ganjae [51]. Their distinct phar-
macological potential is commercially relevant. An increasing number of countries are relaxing
their legislation around C. sativa and its phytocannabinoids. As a result, the global industry
around legal cannabis-derived products is growing rapidly, and is likely to represent a projected
US$ 57 billion market by 2027 [52].
Antimicrobial Effects of Cannabinoids
Cannabis extracts possess antimicrobial activity against the Gram-positive bacteria Bacillus
subtilis and Staphylococcus aureus, as well as against the Gram-negative bacteria Escherichia
coli and Pseudomonas aeruginosa, but exhibits no activity towards the pathogenic fungiCandida
albicans and Aspergillus niger [53]. When tested individually, the major cannabinoids CBG, CBD,
CBC, Δ9-THC, and CBN display antibiotic activity against methicillin-resistant Staphylococcus
aureus [54]. Δ9-THC and CBD exhibit bactericidal effect against Gram-positive staphylococci
and streptococci in the 1–5 μg/ml range, but not against Gram-negative bacteria [55]. ThisTrends in Plant Science, October 2020, Vol. 25, No. 10 989
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as some of the terpenoids, are responsible for the bactericidal effects towards Gram-negative
bacteria. DCA and GFA from Albatrellus dispansus also displayed antimicrobial activity against
Gram-positive bacteria [21]. This activity is attributed to the presence of a prenyl group in DCA
and GFA because the resorcinolic core alone shows no antimicrobial activity [54]. Interestingly,
the prenyl moieties show structural similarities to bioactive monoterpenes.
Bioactivities of Cannabis Cannabinoids
Neutral Cannabinoids
In human, cannabinoids display a variety of bioactivities owing to their interaction with the G
protein-coupled cannabinoid receptors (GPCRs) CB1 and CB2, transient receptor potential
(TRP) ion channels, and peroxisome proliferator-activated receptor γ (PPARγ) [13,56–58].
CB1 is the most abundant GPCR in the central nervous system [59]. CB2 is located predom-
inantly in cells and tissues of the immune system [59]. Some of the medical properties attrib-
uted to the different cannabinoids as specified later require validation by thorough scientific
studies [60].
Δ9-THC exerts pleiotropic effects in humans, including analgesic responses, relaxation, dyspho-
ria, tolerance, and dependence [61]. This reflects agonistic effects ofΔ9-THC on CB1 activation of
β-arrestin 2 recruitment and signaling [61,62]. Δ9-THC is the major psychoactive constituent of
Cannabis [49]. The drug dronabinol (Marinol®) contains Δ9-THC in sesame oil, and is marketed
as an efficient antiemetic for patients receiving cancer chemotherapy and as an appetite stimulant
for persons with acquired immunodeficiency syndrome (AIDS). Doses tailored for chronic
administration positively affected weight and appetite [2]. Δ9-THC is also used to improve
sleep [63]. Δ8-THC is an isomer of Δ9-THC that exhibits a similar although slightly weaker
activity profile on cannabis receptors [1,64]. Δ8-THC can reduce intraocular pressure in
humans and therefore displays antiglaucoma activity [64].
In human, CBD exerts its pharmacological effect on the central nervous system and periph-
eral regions through its high-potency antagonistic activity on CB1 and CB2 as well as by
serving as an allosteric modulator of the μ-opioid receptor [65]. CBD has no toxic effects
in humans at doses between 10 and 700 mg, and is administered in a highly purified
form as Epidiolex® to patients with treatment-resistant epilepsy associated with CDKL5 de-
ficiency disorder and several syndromes [66,67]. CBD has also been assigned anticonvul-
sive, antianxiety, antipsychotic, antinausea, and antirheumatoid arthritis properties [68].
CBD is not psychoactive and has low to no side effects when administered at recom-
mended levels in pharmacotherapy [69]. Administration of CBD decreases Δ9-THC-elicited
psychotic symptoms and reduces the negative impact of Δ9-THC on hippocampus-
dependent memory [70].
CBG is an additional non-psychoactive phytocannabinoid that has low affinity for CB1 and CB2
(~500-fold lower than Δ9-THC), but has significant activity towards several ligand-gated cation
channels of the TRP superfamily. It acts as an agonist of TRPV1 (TRP type vanilloid 1) and
TRPA1 (TRP type ankyrin 1), and as a potent inhibitor of TRPM8 (TRP type melastatin 8) [71–73].
CBC is non-psychotropic and does not interact with CB1 and CB2, but inhibits
endocannabinoid inactivation and activates TRPA1, resulting in protective effects against intes-
tinal inflammation in experimental model systems [74]. CBC resulted in dose-dependent anti-
inflammatory activity in a lipopolysaccharide-induced paw edema model [75]. As of 2020, no
human study with CBC is available.990 Trends in Plant Science, October 2020, Vol. 25, No. 10
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glucose intolerance [76]. Δ9-THCV and CBD are both suggested as possible therapeutic agents
for the treatment of obesity- and metabolic syndrome-related hepatosteatosis [77–79]. In a
double-blind placebo-controlled study, Δ9-THCV significantly decreased fasting plasma glucose,
improved pancreatic β cell function, adiponectin, and apolipoprotein A, whereas plasma high-
density lipoprotein was unaffected [80].
Cannabinoid Acids
The cannabinoid acids produced by C. sativa include Δ9-THCA, CBDA, CBGA, and CBCA.
These compounds do not show any cannabimimetic (i.e., psychotropic) effects [81]. Most
Δ9-THCA samples contain low amounts of Δ9-THC because of spontaneous decarboxylation.
This lability hampers clinical applications. Upon chemical synthesis, Δ9-THCA can be obtained
in two isoforms, named Δ9-THCA-A and Δ9-THCA-B. The biosynthesis in C. sativa is
regiospecific and only results in the formation of Δ9-THCA-A. Δ9-THCA binds to PPARγ
with higher affinity than Δ9-THC and displays low affinity at CB1 and CB2 [82,83]. In mice
treated with 3-NPA, Δ9-THCA acts as a neuroprotective via a PPARγ-dependent pathway
[83]. Δ9-THCA-enriched fractions of ethanol extracts from unheated C. sativa inhibit tumor
necrosis factor α levels in culture supernatants from U937 macrophages and peripheral
blood macrophages in a dose-dependent manner after stimulation with lipopolysaccharide
[84]. Δ9-THCA and Δ9-THC also show distinct effects on phosphatidylcholine-specific phos-
pholipase C activity, but via different pathways [84].
CBDA produces dose-dependent antihyperalgesia and anti-inflammatory effects in mice with
carrageenan-induced acute inflammation [85]. In addition, CBDA (or Δ9-THC) administered by
oral gavage 60 minutes before carrageenan produced antihyperalgesia effects. CBDA (and
CBD) induced a reduction in resting tissue tension of isolated intestinal segments of house
musk shrews via a non-neuronally mediated pathway (i.e., independently of binding to CB1 or
CB2) [86].
Bibenzylic Cannabinoids
Bibenzylic (aralkylic) analogs of CBG (bibenzyl-CBG) from H. umbraculigerum and some liver-
worts contain a phenethyl side chain instead of a pentyl side chain. Compared with CBG,
bibenzyl-CBG displays decreased affinity for the metabotropic CB1 and CB2 receptors but
retains affinity for the ionotropic receptors TRPV 1–4 and TRPA1, and exhibits increased affinity
towards TRPM 8 [14]. These compounds belong to the amorfrutin class of compounds isolated
from Amorpha fruticosa and Glycyrrhiza foetida. Amorfrutins are natural activators of PPARγ and
exert potent anti-inflammatory effects [13,87].
Perrottetinene is a bibenzylic cannabinoid produced by the liverworts Radula perrotteti [18],
Radula marginata [88], and R. laxiramea [89]. Structurally, it resembles Δ9-THC, distinguishing
itself with an aromatic instead of a pentyl side chain. Perrottetinene is a psychoactive CB1 agonist
that induces the behavioral tetrad of hypothermia, catalepsy, hypolocomotion, and analgesia.
Interestingly, the cyclohexene ring of perrottetinene has a stereochemical cis configuration as
opposed to the trans configuration of trans-Δ9-THC. In contrast to the situation in higher plants,
the production of enantiomers is a hallmark of liverwort specialized metabolism [39].
Rhododendron Cannabinoids
Prenylated orcinoids and their derivatives from Rhododendron spp. display various bioactivities,
particularly in the immune system [90,91]. Most of these phytocannabinoids share a chromane/
chromene scaffold and are grouped into CBC or CBL types. They are associated with anticancer,Trends in Plant Science, October 2020, Vol. 25, No. 10 991
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toxicity in humans [92]. Daurichromenic acid (DCA) and rhododaurichromenic acids A and B
exert the most effective anti-HIV activities, as monitored using acutely infected H9 cells. DCA
has a half-maximal effective concentration (EC50) of 15 nM [38], lower than the EC50
value for the positive control drug azidothymidine (44 nM) [93]. Furthermore, DCA displayed
anti-HIV activity with an EC50 of 5.67 ng ml
−1 and a therapeutic index (TI) of 3710 [94].
Rhododaurichromanic acid A also showed potent anti-HIV activity, with an EC50 of 370 ng ml
−1
and a therapeutic index of 92 [94]. Anthopogocyclolic acid (CBL-type), anthopogochromenic
acid (CBL-type), and cannabiorcichromenic acid (CBC-type) from R. anthopogonoides inhibit his-
tamine release and thus exhibit antiallergic effects [11,12,91].
The focus on possible effects and synergies of Δ9-THC and CBD in most pharmacological
studies has resulted in under-representation of the minor cannabinoids in clinical trials. The low
abundance of the minor cannabinoids in the plant renders their possible pharmacological effects
non-obvious and their acquisition for initial trial experiments difficult and expensive. The other
plant sources of cannabinoids do not accumulate cannabinoids at high levels and are often en-
dangered species. This underpins the demand for biotechnology-based production of the rare
cannabinoids to obtain an understanding of their possible contributions to phytocannabinoid-
based medications. A prerequisite for such an approach is knowledge of the biosynthetic path-
ways that generate cannabinoids in Cannabis sativa, Rhododenron dauricum, and Radula
marginata.
Biosynthesis and Biotechnological Production of Cannabinoids
Biotechnology-based production of cannabinoids requires a biological system that can provide a
cellular supply of the precursor isoprenoid units, coordinated expression of all the genes
encoding the enzymes catalyzing the entire biosynthetic pathway for the desired cannabinoid,
and eventually enzyme engineering to utilize specific starter molecules. Currently known plant
sources from which the biosynthetic genes can be obtained are Cannabis sativa, Rhododendron
dauricum, and Radula marginata. A synthetic biology approach would likely involve combinatorial
uses of the genes encoding biosynthetic enzymes with optimal catalytic properties independently
of the plant species. Functional interaction to avoid autotoxicity from the accumulation of high
levels of intermediates is also a selection parameter in such approaches.
Cannabinoid Biosynthesis in Cannabis sativa
The pathway for phytocannabinoid biosynthesis in Cannabis has recently been elucidated
(Figure 3) [95, T. Gülck et al., unpublished]. The pathway is split between different cell types
and organelles: the cytosol of the gland cells, the plastids, and the extracellular storage cavity.
Starting in the cytosol, the precursor molecule hexanoic acid is most likely made available through
oxidative cleavage of fatty acids, such as palmitic acid. The geranyl diphosphate (GPP) used for
prenylation of olivetolic acid (OA) originates from the methylerythritol 4-phosphate (MEP)
pathway, which typically operates in plastidial organelles in eukaryotic cells (normally
chloroplasts) [96]. Oxidative cyclization and storage of the final products take place outside the
gland cells in the resin cavity [97,98]. It remains to be resolved how the pathway intermediates
are transported between the different compartments. Most likely transport proteins and vesicle
trafficking play key roles in mobilizing intermediates across the morphologically highly specialized
interface between the gland cells and the storage cavity (Figure 3).
The biosynthesis of cannabinoids involves integration of key steps in polyketide and isoprenoid
metabolism. Hexanoic acid is used as the polyketide starter molecule and is most likely generated
from C18 fatty acids, that are sequentially desaturated, peroxygenated, and cleaved into a C6992 Trends in Plant Science, October 2020, Vol. 25, No. 10
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peroxide lyases, respectively. This pathway to C6 alkyl compounds was suggested by Stout et al.
[99], supported by Livingston et al. [25] who observed high desaturase, lipoxygenase (LOX), and
hydroperoxide lyase (HPL) expression in trichome-specific transcriptomes. In a reaction cata-
lyzed by acyl-activating enzyme 1 (AAE1), hexanoic acid is converted into the activated thioester
hexanoyl-CoA [99] that is elongated with malonyl-CoA as a C2 donor in a reaction catalyzed by
olivetol synthase (OLS) and cyclized by olivetolic acid cyclase (OAC) to produce olivetolic acid
(OA) [100,101]. The production of OA from hexanoic acid takes place in the cytosol.
GPP (C10 isoprenoid) is synthesized by the plastidial non-mevalonate-dependent isoprenoid
(MEP) pathway, as shown by incorporation studies with 13C-labeled precursors [96].
Cannabigerolic acid synthase (CBGAS, CsaPT4) uses GPP to prenylate OA, forming the
branch-point intermediate and the first bona fide cannabinoid compound CBGA. CBGA is the
direct precursor for the common cannabinoids which are decorated with an alkylic pentyl side
chain [95, T. Gülck et al., unpublished,102]. CBGAS is a transmembrane aromatic
prenyltransferase (aPT) and carries a plastid localization signal. It remains to be determined into
which plastid membrane CBGAS is integrated and whether its active site faces the inner or the
outer side of that membrane. The flavoproteins Δ9-tetrahydrocannabinolic acid synthase
(THCAS) and cannabidiolic acid synthase (CBDAS) are secreted into the extracellular space
and convert CBGA to Δ9-THCA and CBDA, respectively. These conversions proceed as oxida-
tive cyclization reactions, via reduction of molecular oxygen (O2), that generate hydrogen peroxide
(H2O2) as a side-product [97,103]. The reaction mechanism for cannabichromenic acid synthase
(CBCAS) is most likely also dependent on FAD and O2 even though the enzyme was initially
reported to be independent of flavin cofactors and O2 [104]. At that time, CBCAS, CBDAS,
and THCAS were all considered to be oxidoreductases that required neither cofactors nor coen-
zymes [104–106]. CBDAS and THCASwere subsequently characterized as flavoproteins that are
strictly dependent on the presence of O2 as an electron acceptor, as was daurichromenic acid
synthase (DCAS; see later) [38,103]. The high sequence similarity between CBCAS and
THCAS (96% at the nucleotide level) indicates that CBCAS is an O2-dependent flavoprotein
that catalyzes the oxidocyclization of CBGA to CBCA with H2O2 as side-product. All these
oxidocyclases carry a secretion signal peptide and are exported to the extracellular resin space
[6,103,107]. THCAS and CBDAS are catalytically active in the resin space, but it remains to be
demonstrated whether their activity is exclusive to the extracellular space [97].
Δ9-THCA, CBDA, and CBCA are the end-products of the enzymatic biosynthesis of cannabi-
noids with a pentyl side chain. When exposed to heat (pyrolysis during smoking or baking), radi-
ation, or spontaneously during storage, the compounds undergo decarboxylation and
'spontaneous rearrangement' reactions (Figure 2) [1,108].
Cannabinoids with unusual alkyl side chains (C1–C4) are produced by the same enzymes, but
from the respective short-chain fatty acyl-CoAs and with lower affinity (acetyl-CoA, propanoyl-
CoA, butanoyl-CoA, or pentaoyl-CoA, respectively) [1,79,95].Figure 3. Proposed Subcellular Distribution of Enzymes Catalyzing Phytocannabinoid Biosynthesis in Cannabis sativa (left) and Rhododendron
dauricum (right). Enzymes are located in the cytosol (yellow), plastids (green), or apoplastic space (white). Question marks indicate unknown transport mechanisms.
Polyketide formation takes place in the cytosol, prenylation in the plastid, and oxidocyclization and storage in the apoplast. Abbreviations: AAE1, acyl-activating
enzyme 1; ADH, alcohol dehydrogenase; CBCA, cannabichromenic acid; CBCAS, cannabichromenic acid synthase; CBDA, cannabidiolic acid; CBDAS, cannabidiolic
acid synthase; CBGA, cannabigerolic acid; CBGAS, cannabigerolic acid synthase; CsaPT4, C. sativa aromatic prenyltransferase 4; DCA, daurichromenic acid; DCAS,
daurichromenic acid synthase; GA, grifolic acid; HPL, hydroperoxide lyase; LOX, lipoxygenase; MEP, methylerythritol 4-phosphate; OAC, olivetolic acid cyclase;
OLS, olivetol synthase; ORS, orselinic acid synthase; RdPT1, R. dauricum prenyltransferase 1; Δ9-THCA, Δ9-tetrahydrocannabinolic acid; Δ9-THCAS,
Δ9-tetrahydrocannabinolic acid synthase.
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Rhododendron dauricum produces the phytocannabinoid DCA. All carbon atoms in DCA are de-
rived from acetyl-CoA and farnesyl-CoA, with orsellinic acid (OA) and grifolic acid (GA) as key in-
termediates [38,90,109,110]. Specialized glandular scales on the surface of predominantly young
leaves are the place of DCA biosynthesis and storage [38]. The morphology of the scales is differ-
ent from that of the capitate stalked trichomes in Cannabis sativa, being defined by an expanded
cap that comprises central cells and rim cells without an obvious secretory cavity [38]. As in
C. sativa, the phytocannabinoid biosynthesis is split between processes taking place in the cyto-
sol (polyketide pathway), the plastid (MEP pathway and RdPT1 activity), and the apoplastic
space, where DCA, confluentin and other hydrophobic metabolites such as essential oils accumu-
late [37]. GA and DCA are phytotoxic compounds that induce cell death in cell cultures of
R. dauricum [9]. H2O2 formed as a side product in DCA biosynthesis also induces apoptosis-
related reactions resulting in cell death, albeit at increased concentrations in comparison with GA
and DCA. To avoid autotoxicity and cellular damage, the accumulation of DCA is therefore likely
to take place in the apoplast. An increased concentration of H2O2 alongside DCA on the outer
rim of the glandular scales may fortify the plant self-defense system [9]. For the DCAS-catalyzed
reaction to take place, the phytotoxic GA must be exported from its intracellular site of synthesis
before it can exert a detrimental effect. The subcellular transport mechanisms in R. dauricum are
not yet understood and remain an interesting scientific challenge to address.
The DCA pathway begins with chain extension of acetyl-CoA by the type III polyketide
synthase (PKS) orcinol synthase (ORS) in a reaction where three units of malonyl-CoA are
the carbon donor (Figure 3). The predominant product of recombinant and purified ORS is
orcinol; orsellinic acid (OSA), triacetic acid lactone, phloroacetophenone, and tetraacetic acid
lactone are minor products. OSA is the substrate for the subsequent reaction, but not orcinol.
Interestingly, it was found that addition of purified C. sativa olivetolic acid cyclase (OAC) to ORS
led to an increase in OSA production and a concomitant decrease in orcinol production in an
OAC dose-dependent manner [90]. Thus, the existence of a non-identified tetraketide cyclase
in R. dauricum was suggested.
The regiospecific farnesylation step is catalyzed by the aromatic farnesyltransferase RdPT1.
Surprisingly, the farnesyl-CoA is derived from the plastidial MEP pathway, as shown by inhibitor
studies. Inhibition of the MEP pathway with clomazone led to a decrease in OSA and DCA,
whereas inhibition of the mevalonate-dependent pathway with mevastatin led to their increase,
probably owing to compensatory upregulation of theMEP pathway [109].RdPT1 showsmoderate
sequence identity to known UbiA aromatic PTs and is localized within the plastid compartment
(Figure 3) [109].RdPT1may use geranyl-CoA and geranylgeranyl-CoA as alternative prenyl donors
but at activity rates of only 13% and 2.5% of the activity obtained with farnesyl-CoA. Lastly, the
cannabichromene (CBC) scaffold is formed in an oxidative cyclization reaction catalyzed by the
flavoprotein DCA synthase (DCAS) [38]. Similarly to the oxidocyclases THCAS and CBDAS from
C. sativa, DCAS is secreted and is enzymatically active outside in the apoplastic space. The
reaction proceeds with concomitant release of H2O2 [38]. Confluentin is the decarboxylated form
of DCA and has been isolated from R. dauricum [111]. It is possibly produced by spontaneous
decarboxylation upon irradiation, heat, and storage, comparable with the slow decarboxylation
of acidic cannabinoids to the neutral forms in C. sativa glandular trichomes [1].
In a synthetic biology-based approach, combinatorial biosynthesis of DCA as well as of a haloge-
nated derivative of DCA was established in Aspergillus oryzae NSAR1, using genes from the
fungus Stachybotrytis bisbyi PYH05-7 and Fusarium sp. in combination with RdDCAS [112].
The type I PKS StbA chain was found to elongate the starter molecule acetyl-CoA, usingTrends in Plant Science, October 2020, Vol. 25, No. 10 995
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core OSA. Using farnesyl-CoA as a donor and OSA as the acceptor, the UbiA prenyltransferase
StbC was used to biosynthesize GFA [112] which was converted into DCA using the RdDCAS
enzyme. The halogenase AscD from Fusarium was used to introduce a chlorine atom on the
aromatic ring, forming 5-chloroDCA. Cyclization of the halogenated GA by RdDCAS was not
affected by the presence of the halogen atom [112]. Halogenated meroterpenoids derived from
OSA display bioactivity [112].
Biosynthesis of Bibenzyl Cannabinoids in Radula marginata
Mining of a de novo assembled Radula marginata transcriptome published in 2018 afforded
candidate genes for enzymes in GPP synthesis [113]. Stilbene acid or dihydrostilbene acid
were indicated as the key precursor for synthesis of the bibenzyl CBGA analog [113]. Stilbene
acids are rare in nature, but compounds of this type are present in Hydrangea macrophylla var.
thunbergii (hydrangic acid, lunularic acid) [114], liverworts such as Marchantia polymorpha
L. (prelunularic acid and lunularic acid) [115], and Convolvulus hystrix [116].
Stilbene acids are most likely biosynthesized from a type III PKS using common CoA-activated
precursor molecules such as coumaroyl-CoA or dihydrocoumaroyl-CoA [117]. These starter
molecules are extended with units of malonyl-CoA via decarboxylation involving condensation
reactions, generating a polyketide intermediate that, depending on the enzyme systems present,
may give rise to different core structures [117]. In the case of hydrangic acid, the starter molecule
is thought to be coumaroyl-CoA, which is then extended using three units of malonyl-CoA as a C2
donor to produce a tetraketide intermediate in a reaction catalyzed by an unknown stilbene
synthase (STS)-type PKS enzyme. Reduction of the polyketide chain by a ketoreductase (KR)
is then thought to be followed by an STS-like C2-to-C7 intramolecular aldol condensation [118]
in which unusual retention of the carboxylic group generates hydrangic acid. The possible
involvement of a KR is based on the lack of the C5-hydroxyl group on the aromatic ring of the
hydrangic acid compared with the structure of stilbene acid. The loss of the hydroxyl group
can be explained by cyclization with a reduced C5 carbonyl group of the tetraketide [118].
Prelunularic acid, the precursor for lunularic acid, is most likely formed by a type III PKS, called
bibenzyl synthase (BBS), that uses dihydrocoumaroyl-CoA as the starter molecule for extension
with three units of malonyl-CoA as the carbon donor [117,118]. It is likely that the cyclization also
takes place on a reduced polyketide given the observed lack of a hydroxyl group at position C5 of
the A ring [114,115,118]. In both cases, the retention of the carboxylic group is unusual for an
STS, leading to the proposition that the STS enzymes involved in the synthesis of bibenzyl
cannabinoids represent a novel class of type III PKS enzymes that have an altered carboxylate-
retaining reactionmechanism, and that the KR enzyme involved has acquired the additional ability
to catalyze the cyclization or that a hypothetical cyclase might assist in the formation of the ring
[114,118]. The discovery of the dimeric α + β barrel protein olivetolic acid cyclase (OAC) in
C. sativa represented the first plant enzyme that catalyzes the proposed C2–C7 intramolecular
aldol condensation with carboxylate retention [101]. Structural analyses of OAC disclosed a
unique active-site cavity containing the pentyl-binding hydrophobic pocket and the polyketide
binding site, as well as a lack of thioesterase and aromatase activities [119]. In summary, the
stilbene acid or dihydrostilbene acid precursor in R. marginata is likely derived from coumaroyl-
CoA or cinnamoyl-CoA, respectively, which is chain-elongated by a type III PKS and cyclized
by a putative tetraketide cyclase (dihydrostilbene acid cyclase, DHAC).
R. marginata produces perrottetinenic acid. The transcriptome of this liverwort harbors an mRNA
sequence encoding a type III PKS identified as a stilbene acid synthase (RmSAS) and that996 Trends in Plant Science, October 2020, Vol. 25, No. 10
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Marchantia polymorpha (PDB ID 2P0U) [113]. This PKS is most likely responsible for chain elon-
gation of the aromatic precursor (Figure 4). Other putative enzymes involved in the biosynthesis of
perrottetinenic acid are a double-bond reductase (DBR) that generates dihydrocinnamoyl-CoA
from the phenylpropanoid precursor, an aromatic prenyltransferase (RmaPT), and an
oxidocyclase (perrottetinenic acid synthase, PAS). Assuming that the biosynthesis of the bibenzyl
cannabinoids is distributed across the liverwort cells in a similar manner as the biosynthetic path-
ways in Cannabis and Rhododendron, transcripts encoding the respective enzymes should be
expressed accordingly. Hence, DBR and DHAC should localize to the cytosol, the RmaPT to
the plastid, and the PAS to the oil body. Corresponding signal peptides might serve as indicators
for selection of the encoding genes. Table 1 presents an overview of currently known pathway
genes. The table also highlights the knowledge gaps in pathway discovery, and genes used for
secondary modifications of cannabinoids.
Biotechnological Production of Phytocannabinoids in Heterologous Hosts
Cannabinoids can be produced using biotechnology approaches using different production plat-
forms including plants, fungi, and bacteria. Comparison of these production platforms is beyond
the scope of this review, but ample literature is available on the latest advances. C. sativa-based
production of cannabinoids using explants and micropropagation has been reviewed by Lata
et al. [120] and Schachtsiek et al. [121], and was recently expanded by Kodym and Leeb
[122]. In addition to C. sativa, the high-biomass crop Nicotiana benthamiana was identified as
a promising heterologous host to produce cannabinoids in planta. N. benthamiana is an
established production platform for proteins and bioactive natural products [123–126], and pos-
sesses glandular trichomes that can be utilized to avoid autotoxicity resulting from cannabinoid
pathway intermediates [121]. The use of in vitro plant cell cultures for cannabinoid production
covering genetic transformation, cell suspension cultures, hairy/adventitious roots, and heterolo-
gous systems has been reviewed [127]. Yields of 1.04 μg Δ9-THCA g−1 dry weight have been
obtained in hairy roots [128] and 0.121 g Δ9-THCA l−1 h−1 from direct precursor feeding [129].
Microbial production of cannabinoids remains limited [93, T. Gülck et al., unpublished]. Produc-
tion of cannabinoids from galactose was achieved in Saccharomyces cerevisiae [95], reaching
titers of 1.4 mg l−1 CBGA, 2.3 mg l−1 Δ9-THCA, and 8.0 mg l−1 CBDA. Their platform also led
to the production of minor cannabinoids including tetrahydrocannabidivarinic acid (Δ9-THCVA;
4.8 mg l−1) and cannabidivarinic acid (CBDVA; 0.006 mg l−1).
Synthetic Biology Approaches in Phytocannabinoid Production
As discussed earlier, phytocannabinoids are terpenophenolic compounds whose precursors are
provided by the polyketide and MEP isoprenoid biosynthetic pathways. In heterologous produc-
tion systems, optimizing and engineering these two pathways to provide adequate amounts
of the initial precursors is an obvious challenge. In the biosynthesis of cannabinoids, these two
pathways are linked by the action of aromatic prenyl transferases. Aromatic prenyltransferases
are ubiquitous in animals [130], plants [131], fungi [132], and bacteria [133] and their different
reaction spectra serve to diversify the production of aromatic metabolites such as the
phenylpropanoids, flavonoids, and coumarins in plants [134]. In combination with modules
involved in phytocannabinoid synthesis in different species of higher plants, liverworts, and
fungi, the option arises to use an aromatic prenyltransferase-based approach for the production
of new-to-nature phytocannabinoids in heterologous hosts based on combinatorial uses of the
modules across species. Likewise, coexpression of specific pairs of aromatic prenyltransferases
may result in increased phytocannabinoid production or altered product profiles if new catalytic
patterns arise as a result of heterodimerization [T. Gülck et al., unpublished]. The availability of ar-
omatic prenyl transferases with different donor and acceptor preference specificities thusTrends in Plant Science, October 2020, Vol. 25, No. 10 997
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rial approaches in the diterpenoid area have given rise to new-to-nature core structures [135].
Like the hop plant (Humulus lupulus) [136],C. sativa also expresses chalcone isomerase-like pro-
teins (CHILs) in trichomes. These are polyketide-binding proteins, and coexpression of these
CHIL genes in heterologous cannabinoid-producing systems may serve to boost production
levels [T. Gülck et al., unpublished].
In addition to combinatorial biochemistry, enzyme promiscuity may be used successfully to
incorporate non-natural precursors such as pentanoic acid, heptanoic acid, 4-methylhexanoic
acid, 5-hexenoic acid, and 6-heptynoic acid into the cannabinoids produced. Functionalization
of the side chain with an alkene or alkyne terminal group would enable post-fermentation click-
chemistry-based modifications, as illustrated by copper-catalyzed azide–alkyne cycloaddition
onto the 6-heptynoic acid analogs of CBGA and Δ9-THCA with an azide conjugate [95].
The functionality of phytocannabinoids may be further diversified by other types of derivatization
[T. Gülck et al., unpublished]. Glycosylationmay serve to avoid autotoxicity in the production host,
increase solubility, and in a therapeutic context improve the absorption, distribution, metabolism,
and excretion (ADME) characteristics of a drug candidate. Collections of regio- and substrate-
specific glycosyltransferases to carry out such modification reactions are available [T. Gülck
et al., unpublished, 137]. Derivatization using acyltransferases or halogenation reactions offers
additional opportunities. GA and DCA were successfully halogenated by coexpression of the
halogenase AscD from Fusarium sp. [112]. Halogenation of GA did not hamper the conversion
to DCA by DCAS. Halogenated natural products occur predominantly in marine sources and
can display antibacterial, antifungal, antiparasitic, antiviral, antitumor, anti-inflammatory, and
antioxidant activities [138]. With these options at hand, synthetic biology will have a major
impact on the design of phytocannabinoids with optimal properties for specific uses.
Possible Storage of High Amounts of Cannabinoids in Natural Deep Eutectic
Solvents to Maintain Cell Homeostasis
The resin inside glandular trichomes of C. sativa, the apoplast of glandular scales in R. dauricum,
and oil bodies in R. marginata are the storage environments and sites of the oxycyclase-catalyzed
last step in the synthesis of cannabinoids [5,37,40,97]. 1H NMR-basedmetabolomics ofC. sativa
trichomes revealed co-storage of the cannabinoids with an abundance of sugars, amino acids,
choline, organic acids, and terpenes [5]. Sugars, choline, and organic acids are typical constitu-
ents that, when present in appropriate stoichiometric ratios, form natural deep eutectic
solvents (NADESs) [139]. NMR studies demonstrate that NADES-forming constituents exhibit
proton mediated intermolecular interactions resulting in their aggregation into larger structures
in the liquid phase [140]. NADESs are eminent solvents for natural products and retain this
property when the water content is below 40% [141]. Based on these observations, NADESs
have been proposed to embody a third membrane-less solvent phase in biological systems
[139,142–146]. Δ9-THCA and CBDA are virtually insoluble in water, thus supporting NADES-
mediated solubilization in glandular trichomes and oil bodies [64,147]. The catalytic activity of
the oxidocyclases THCAS, CBDAS, and DCAS within the trichome compartments of C. sativa
and R. dauricum is accompanied by the release of stoichiometric amounts of H2O2 [97].Figure 4. Proposed Biosynthetic Pathways for Lunularic Acid and Perrottetinene. Green highlighted structures
represent compounds isolated from Radula perrotteti or R. marginata. Lunularic acid, a common liverwort phytohormone
contains a bibenzyl-core, but lacks the C5-hydroxy group. Abbreviations: DBR, double-bond reductase; GPP, gerany
diphosphate; KR, ketoreductase; Mal-CoA, malonyl-CoA; PKS, polyketide synthase; Put., putative.
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Outstanding Questions
The biosynthetic pathways for
amorfrutins in Amorpha fruticosa,
Helichrysum umbraculigerum, and
Glycyrrhiza foetida are unknown.
Elucidation of their biosynthesis might
provide cannabinoid specific O-
methyltransferases and alternative aro-
matic precursors as new modules for
use in combinatorial approaches to
build new cannabinoid structures.
In cannabinoid biosynthesis, autotoxic
intermediates and end-products such
as CBGA, CBDA, GFA, and DCA are
generated and safely accumulated in
specialized storage organs such as
capitate stalked trichomes, glandular
scales, or extracellular storage cavities.
How are the intermediates and end-
products formed and transported
without exerting toxicity? Does vesicle
trafficking play a key role in enabling
the compounds to cross the morpho-
logically highly specialized interface be-
tween the gland cells and the storage
cavity?
The oxidocyclases catalyzing the last
steps in cannabinoid synthesis in
Cannabis sativa are secreted into the
non-aqueous storage space, where
they retain their enzymatic activity.
Does the oxidocyclization reaction
take place exclusively in the apoplastic
space to protect the gland cells, or
does the reaction already take place
during transport (e.g., inside transport
vesicles)?
NADES have been proposed as a third
phase in biological systems. Do
NADES provide a specific reaction
and/or storage space for cannabinoids
in cannabis, rhododendron, and
liverworts?
The biosynthetic pathways of
cannabinoids are being investigated,
but very little is known about their
regulation. It is known that the
stochiometric balance between for
example OLS and OAC is crucial
to avoid the accumulation of
unwanted autocyclization products
of the tetraketide intermediate.
Which transcriptional, translational,
and post-translational mechanisms are
in operation to optimize the pathway
fluxes? Which mechanisms respond to
environmental changes?
Table 1. Enzymes Involved in Phytocannabinoid Biosynthesis or Cannabinoid Metabolism
Organism Biosynthetic role Enzyme GenBank accession Refs
C. sativa Precursor supply AAE1 JN717233.1 [99]
Type III PKS TKS AB164375.1 [100]
Tetraketide cyclase OAC JN679224.1 [101]
C-Prenyltransferase CBGAS BK010648.1 [95]
Oxidocyclase THCAS AB057805.1 [6]
CBDAS AB292682.1 [106]
CBCAS N/Aa [104]
R. dauricum Precursor supply Unknown
Type III PKS ORS LC133082.1 [90]
Tetraketide cyclase Unknown
C-prenyltransferase RdPT1 N/A [109]
Oxidocyclase DCAS LC184180.1 [38]
R. marginata Precursor supply Unknown
Type III PKS Putative SAS N/A [113]
Tetraketide cyclase Unknown
C-prenyltransferase Unknown
oxidocyclase Unknown
S. bisbyi PYH05-7 Type I PKS StbA LC125467.1 [112]
S. bisbyi PYH05-7 C-Prenyltransferase StbC LC125467.1 [112]
Secondary modifications
S. bisbyi PYH05-7 Reductase StbB LC125467.1 [112]
Fusarium sp. Halogenase AscD LC228576.1 [112]
H. sapiens Monooxygenase CYP3A4 NM_017460.6 [149]
Stevia rebaudiana O-Glycosylation UGT71E1 AY345976.1 [150]
Oryza sativa O-Glycosylation UGT5 XP_015622068.1 [151]
aN/A, not available.
Trends in Plant ScienceNevertheless, they retain their enzyme activity despite insignificant catalase activity in the C. sativa
glandular trichomes. NADES embedment may stabilize the oxidocyclases. In parallel with the ability
of a NADES to serve as a biological solvent in which biosynthetic enzymes can remain active, the
storage of large amounts of natural products in a NADES-based separate liquid phase would enable
the plant cell to maintain cell homeostasis [97,139,142]. The cytochrome P450 (CYP) enzymes
CYP79A1 and CYP71E1 and the P450 oxidoreductase involved in synthesis of the cyanogenic
glucoside dhurrin were recently shown to be stabilized in a NADES [148]. In efforts to engineer
the production of high titers of cannabinoids in heterologous hosts, appropriate storage of the
cannabinoids will need to be part of the overall engineering strategy to avoid autotoxicity issues.
Concluding Remarks and Future Outlook
The biosynthetic genes involved in phytocannabinoid biosynthesis across the plant species
reviewed here can be used in a combinatorial fashion to construct desired new-to-nature
phytocannabinoid structures based on combining unique prenyl moieties, side chains, and
cyclized core structures (see Outstanding Questions). Potentially, it is possible to produce any
type of cannabinoid once additional biosynthetic systems have been elucidated and a large
collection of enzyme modules is established and available for additional engineering. The1000 Trends in Plant Science, October 2020, Vol. 25, No. 10
Trends in Plant Sciencemembrane-bound aromatic prenyltransferases catalyze a key step in cannabinoid synthesis and
are envisaged to pose the largest engineering challenges. The discovery of OAC orthologs for
tetraketide cyclization with carboxylate retention, and of type III PKS enzymes specific for diverse
aromatic starter molecules, are promising focus areas. Comparative studies between the type III
PKS from R. dauricum (forming orcinoid cannabinoids) and C. sativa (forming predominantly
olivetoids, but also varinoids) might give insight into their specificity for different starter molecule
structures and allow protein engineering towards desired chain lengths. Secondary modifications
of cannabinoids such as halogenation, oxygenation, and glycosylation may be used to modulate
their physicochemical properties and thus positively affect their pharmacological properties by
improving their bioavailability. Enzymes catalyzing some of these modifications could possibly
be obtained from the C. sativa mycoflora or from the microbiome of humans heavily exposed
to cannabinoids. Semi-synthetic approaches combining biosynthesis with chemical modification
will no doubt offer further types of cannabinoids.
The availability of heterologously produced isolated cannabinoids provides an opportunity to
scrutinize the contributions of individual cannabinoids to the reported therapeutic and psychoac-
tive effects, including specific combinatorial effects. Lastly, quantitative chemical profiling of
glandular scales fromRhododendron dauricum and oil bodies fromRadulamarginata is expected
to provide insights into the occurrence and importance of NADES in offering storage possibilities
in heterologous hosts and thereby avoiding autotoxicity.
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